These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30610579)

  • 21. Comparison of different functional prediction scores using a gene-based permutation model for identifying cancer driver genes.
    Nono AD; Chen K; Liu X
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):22. PubMed ID: 30704472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology.
    Li Y; Zhang Y; Li X; Yi S; Xu J
    Trends Biochem Sci; 2019 Aug; 44(8):659-674. PubMed ID: 31047772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.
    Roukos DH
    Expert Rev Mol Diagn; 2010 Jan; 10(1):33-48. PubMed ID: 20014921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of Random Forest Classifiers and Deep Convolutional Neural Networks for Classification and Biomolecular Modeling of Cancer Driver Mutations.
    Agajanian S; Oluyemi O; Verkhivker GM
    Front Mol Biosci; 2019; 6():44. PubMed ID: 31245384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying cancer driver genes in individual tumours.
    Gillman R; Field MA; Schmitz U; Karamatic R; Hebbard L
    Comput Struct Biotechnol J; 2023; 21():5028-5038. PubMed ID: 37867967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing.
    Zhang J; Liu J; Sun J; Chen C; Foltz G; Lin B
    Brief Bioinform; 2014 Mar; 15(2):244-55. PubMed ID: 23818492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precision medicine driven by cancer systems biology.
    Filipp FV
    Cancer Metastasis Rev; 2017 Mar; 36(1):91-108. PubMed ID: 28265786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
    Roukos DH
    Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network Approaches for Precision Oncology.
    Pai S
    Adv Exp Med Biol; 2022; 1361():199-213. PubMed ID: 35230690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and future molecular profiling of cancer by next-generation sequencing.
    Shibata T
    Jpn J Clin Oncol; 2015 Oct; 45(10):895-9. PubMed ID: 26292697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
    Fang B
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Looking beyond drivers and passengers in cancer genome sequencing data.
    De S; Ganesan S
    Ann Oncol; 2017 May; 28(5):938-945. PubMed ID: 27998972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
    Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
    Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel network control model for identifying personalized driver genes in cancer.
    Guo WF; Zhang SW; Zeng T; Li Y; Gao J; Chen L
    PLoS Comput Biol; 2019 Nov; 15(11):e1007520. PubMed ID: 31765387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward physics-based precision medicine: Exploiting protein dynamics to design new therapeutics and interpret variants.
    Meller A; Kelly D; Smith LG; Bowman GR
    Protein Sci; 2024 Mar; 33(3):e4902. PubMed ID: 38358129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
    Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
    Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
    Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
    CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteogenomics: Key Driver for Clinical Discovery and Personalized Medicine.
    Barbieri R; Guryev V; Brandsma CA; Suits F; Bischoff R; Horvatovich P
    Adv Exp Med Biol; 2016; 926():21-47. PubMed ID: 27686804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The characteristics of lung adenocarcinoma driver gene variants detected by high-throughput sequencing and quantitative fluorescence PCR].
    Chen LF; Chen XY; Lin J; Yu XB; Jin L
    Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):772-778. PubMed ID: 31594041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.